Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

The World Health Organisation (WHO) released new guidelines recommending the use of injectable lenacapavir (LEN) twice a year ...

Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...

WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...

Thailand is examining the feasibility of adopting new global guidelines on long-acting HIV prevention, following the World Health Organisation's (WHO) launch of its latest recommendations for ...

The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...

A new injectable drug known as lenacapavir could change how millions of people across the world and Africa in particular access HIV protective drugs, which historically have hard to come by.Presented ...

Although the FDA approval of lenacapavir as a twice-yearly form of preexposure prophylaxis (PrEP) is “momentous,” cost and access curb excitement, according to Jeremiah Johnson, executive director of ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV ...

Lenacapavir has been incredibly promising in trials and now the World Health Organisation have officially recommended the drug for HIV prevention. Smitha Mundasad explains the difference this ...

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...